Business Description
Sagimet Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US7867001049
Share Class Description:
STU:0O2: Class A SharesDescription
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1314.53 | |||||
| Equity-to-Asset | 0.98 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -78.9 | |||||
| 3-Year EPS without NRI Growth Rate | -73.1 | |||||
| 3-Year FCF Growth Rate | -69.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -31.57 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.42 | |||||
| 9-Day RSI | 61.65 | |||||
| 14-Day RSI | 58.84 | |||||
| 6-1 Month Momentum % | 6 | |||||
| 12-1 Month Momentum % | 47.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.41 | |||||
| Quick Ratio | 38.41 | |||||
| Cash Ratio | 37.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -57.69 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1912.32 | |||||
| ROE % | -25.59 | |||||
| ROA % | -24.75 | |||||
| ROIC % | -550.94 | |||||
| ROC (Joel Greenblatt) % | -18863.45 | |||||
| ROCE % | -31.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.79 | |||||
| PB Ratio | 1.07 | |||||
| Price-to-Tangible-Book | 1.07 | |||||
| EV-to-EBIT | -0.67 | |||||
| EV-to-Forward-EBIT | -0.64 | |||||
| EV-to-EBITDA | -0.67 | |||||
| EV-to-Forward-EBITDA | -0.65 | |||||
| EV-to-Revenue | 15.41 | |||||
| EV-to-Forward-Revenue | 6.16 | |||||
| EV-to-FCF | -0.8 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.24 | |||||
| Earnings Yield (Greenblatt) % | -149.25 | |||||
| FCF Yield % | -21.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sagimet Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.834 | ||
| EPS (TTM) (€) | -1.175 | ||
| Beta | 0 | ||
| Volatility % | 152.48 | ||
| 14-Day RSI | 58.84 | ||
| 14-Day ATR (€) | 0.245163 | ||
| 20-Day SMA (€) | 5.005 | ||
| 12-1 Month Momentum % | 47.22 | ||
| 52-Week Range (€) | 2.22 - 16.7 | ||
| Shares Outstanding (Mil) | 32.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sagimet Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sagimet Biosciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sagimet Biosciences Inc Frequently Asked Questions
What is Sagimet Biosciences Inc(STU:0O2)'s stock price today?
The current price of STU:0O2 is €5.20. The 52 week high of STU:0O2 is €16.70 and 52 week low is €2.22.
When is next earnings date of Sagimet Biosciences Inc(STU:0O2)?
The next earnings date of Sagimet Biosciences Inc(STU:0O2) is 2025-03-25 Est..
Does Sagimet Biosciences Inc(STU:0O2) pay dividends? If so, how much?
Sagimet Biosciences Inc(STU:0O2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers